Generic Medicine Info
Gestational age <24 or >33 wk, premature rupture of membranes >30 wk of gestation, uterine haemorrhage requiring immediate delivery, eclampsia, severe pre-eclampsia, intra-uterine growth retardation w/ abnormal foetal heart rate, intra-uterine foetal death, suspected intra-uterine infection, placenta praevia, abruptio placentae.
Special Precautions
Patient w/ abnormal placental site, intra-uterine growth restriction, multiple pregnancy. Hepatic impairment. Lactation. Monitoring Parameters Monitor uterine contractions and foetal heart rate during use, and blood loss after delivery.
Adverse Reactions
Nausea, vomiting, headache, dizziness, flushes, tachycardia, hypotension, hyperglycaemia, inj site reactions; insomnia, pruritus, rash, pyrexia. Rarely, uterine haemorrhage and atony.
Drug Interactions
Increased risk of pulmonary oedema w/ other tocolytic drugs (e.g. Ca channel blockers, betamimetics).
ATC Classification
G02CX01 - atosiban ; Belongs to the class of other gynecologicals. Used to inhibit uncomplicated premature labour between 24 and 33 weeks of gestation.
Disclaimer: This information is independently developed by CIMS based on atosiban from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in